2025年,中国创新药领域的两则新闻引发全球关注:3月8日,康方生物的PD-1/VEGF双抗药物依沃西单抗,因在《柳叶刀》发布的Ⅲ期临床数据中直接击败默沙东的当家花旦K药,随后又头对头战胜另一位PD-1市场的强者——替雷利珠单抗。百利天恒因一款全球首创EGFR/HER3双抗ADC药物(BL-B01D1)与百时美施贵宝(BMS)达成84亿美元(约600亿元)授权交易,2024年营收暴增936%至...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.